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Background: Clinical practice guidelines globally recommend lifestyle modification including diet and exercise
training as first-line treatment for obesity. The clinical benefits of exercise training in adults with obesity is
well-documented; however, there is no strong evidence for the effectiveness of exercise training for weight
loss in class II and class III obesity. The purpose of the randomised controlled trial described in this protocol
article is to examine the effect of exercise training, in addition to a very low energy diet (VLED), in clinically
severe obese women for changes in body composition, physical function, quality of life, and markers of
cardiometabolic risk.
Methods/Design: Sixty women, aged 18–50 years with a body mass index (BMI) greater than 34.9 kg.m2
and at least one obesity-related co-morbidity, will be recruited for this 12-month study. Participants will be randomised
to either exercise plus energy restriction (n = 30), or energy restriction alone (n = 30). All participants will follow an
energy-restricted individualised diet incorporating a VLED component. The exercise intervention group will also receive
exercise by supervised aerobic and resistance training and a home-based exercise programme totalling 300 minutes
per week. Primary outcome measures include body composition and aerobic fitness. Secondary outcome measures
include: physical function, cardiometabolic risk factors, quality of life, physical activity, and mental health. All outcome
measures will be conducted at baseline, 3, 6 and 12 months.
Discussion: Previous research demonstrates various health benefits of including exercise training as part of a healthy
lifestyle at all BMI ranges. Although clinical practice guidelines recommend exercise training as part of first-line
treatment for overweight and obesity, there are few studies that demonstrate the effectiveness of exercise in class II
and class III obesity. The study aims to determine whether the addition of exercise training to a VLED provides more
favourable improvements in body composition, physical function, quality of life, and markers of cardiometabolic
risk for women with clinically severe obesity, compared to VLED alone.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12611000694910). Date registered: 4 July 2011
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Around one quarter of Australian and one third of US
adults are classified as obese [1, 2]. Further, there is evi-
dence of an acceleration in the prevalence of those
approaching class III obesity (body mass index, BMI
≥40 kg.m2), compared to overweight and class I obese
individuals (BMI 25–34.9 kg.m2) [2–4]. Individuals in
classes II (BMI 35–39.9 kg.m2) and III (BMI ≥40 kg.m2)
obesity are at a higher risk of developing metabolic and
cardiovascular disease, and disability compared to those
with overweight and class I obesity [3, 5, 6]. This trans-
lates to clinical health care costs that are twice that of
healthy-weight individuals [7].
Diabetes mellitus, cardiovascular disease, sleep apnoea,
dyspnoea, mental illness, musculoskeletal pain and dis-
orders all impact negatively on an individual’s capacity
to perform activities of daily living and are more preva-
lent in obese individuals [8–11]. Reduced capacity for
activities of daily living may occur prior to the develop-
ment of these conditions and may be related to adverse
metabolic and biomechanical changes associated with
obesity [12, 13]. Obese individuals often experience a
vicious cycle of low exercise capacity, physical disability
and breathlessness leading to physical inactivity, and fur-
ther weight gain [14], loss of physical function [15, 16],
and frailty [13, 17, 18].
Regular aerobic or resistance exercise training influ-
ences physical fitness and functional capacity through
improvements in muscular strength, power, endurance,
and cardiorespiratory and vascular fitness. Aerobic exer-
cise training specifically facilitates the improvement in
central and peripheral cardiorespiratory, vascular and
metabolic function, while resistance training improves
muscular endurance, strength, power and hypertrophy
[19]. Obese adults have been reported as having a
blunted response to exercise training when exposed to
the same training stimulus as their healthy-weight peers
[20]. The addition of specific exercise training to energy
restriction in obesity may, in addition to changes in
physical fitness, confer favourable body composition out-
comes but the evidence in clinically severe obesity is
limited [21–23].
Lean mass is integral to the long-term maintenance of
metabolic rate, core body temperature, skeletal integrity,
muscle strength, functional capacities [24, 25], and the
prevention of sarcopenic obesity later in life [26]. During
weight loss a greater proportion of lean mass is lost
compared to when weight is regained [27, 28]. The
resulting lean mass deficit and continued lack of physical
activity associated with ageing may lead to increased risk
of physical disability later in life [29, 30]. Exercise in
addition to weight loss improves physical function to a
greater extent than energy-restricted weight loss alone
[23]. It is not clear whether aggressive dietary weightloss with the addition of exercise training is any more
beneficial, compared with dietary weight loss alone, in
clinically severely obese individuals. Although exercise
training during an energy-restricted diet slows the loss
of lean mass [22, 23, 31, 32], exercise training may be
more important as a method to enhance long-term
maintenance of weight loss [33–35].
Clinical practice guidelines recommend exercise train-
ing together with energy restriction as a first-line inter-
vention for obesity, without strong evidence of the
effectiveness of exercise training for weight loss in class
II and class III obesity [36–40]. Even if exercise training
proves to not be effective for weight loss in severely
obese individuals, there are other important benefits to
explore for them. Exercise training alone has been re-
ported to improve glucose regulation and slow the pro-
gression of type 2 diabetes [41–52], reduce systolic and
diastolic blood pressure (BP) [53–60], and reduce total
cholesterol, low-density lipoprotein (LDL) cholesterol,
and triglycerides [59, 61, 62], independent of weight loss
in overweight and obese adults. Improvements have also
been noted for symptoms of depression [63–69] and
quality of life [70, 71] in obese individuals. Individuals
with severe obesity may respond differently to these out-
come measures than overweight individuals. Therefore,
the purpose of the randomised controlled trial described
here is to examine the unique effect of exercise training,
in addition to a very low energy diet (VLED), in women
with severe obesity for changes on body composition,
physical function, quality of life, and markers of cardio-
metabolic risk.
Methods
Design
This randomised clinical trial is summarised in Fig. 1. The
study has been approved by the Deakin University Human
Research Ethics Committee (reference, 2011–154), the
Alfred Human Research Ethics Committee (reference,
330/11) and is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12611000694910). The
trial will be conducted in accordance with the Helsinki
Declaration [72] and reporting of the study will
adhere to the Consolidated Standards of Reporting
Trials (CONSORT) guidelines [73]. Following the ini-
tial screening process, the women will be randomised
into either the energy restriction alone group (ER) or
the energy restriction plus exercise intervention group
(EXER).
Participants
Women aged 18–50 years, with a BMI greater than
34.9 kg.m2 and at least one obesity-related co-morbidity,
will be recruited. Volunteers will be excluded if they
report serious unstable cardiovascular conditions, type 1
Fig. 1 Trial flow chart outlining participant testing and intervention schedule
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ercise participation, pregnancy, planning pregnancy in
the next 12 months or breastfeeding, weight loss greater
than 5 kg in the past 3 months, currently using weight
loss medication or having undergone weight loss surgery
in the past, currently using medication which significantly
influences weight (antipsychotic drugs, some corticoste-
roids, anticonvulsant drugs, Loperamide, Buscopan, insu-
lin), and currently undertaking more than 150 minutes of
moderate to vigorous intensity exercise each week. Each
participant will receive written and verbal explanations
about the nature of the study and the testing procedures.
Those participants who choose to participate must pro-
vide informed consent by signing a participant informa-
tion and consent form and consult with their own general
practitioner to obtain a medical clearance prior to
formally being accepted to participate.
Recruitment
Participants volunteering for the study will be recruited
through Deakin University, Monash Medical, and Baker
IDI Heart and Diabetes Institute internal email net-
works. Advertisements will be placed in one large locally
subscribed weekend newspaper and other local area
newspapers. Study details and contact details will be
listed on the Baker IDI Heart and Diabetes volunteer
webpage, promoted on social media (Facebook and
Twitter). One-page information flyers will be given to
medical practices in the local area after meeting with
practice nurses and dietitians, and flyers placed in med-
ical practice waiting rooms. Interested volunteers self-
initiate contact with the research team via email or
phone. Interested volunteers will be screened against
the inclusion criteria prior to being given the partici-
pant information and consent form, and medical
clearance form.Sample size
The number (n = 60) of participants to be recruited for
this study has been determined based on previous evi-
dence, plus a projected drop-out rate of 25 %, and pro-
vide adequate statistical power for the two co-primary
outcome measures of VO2peak (n = 20, α = 0.05, power
0.9 [74]) and lean mass (n = 23, SD of 1.7, α = 0.05,
power 0.8 [75]). Secondary outcome measures for trad-
itional markers of cardiometabolic health including sys-
tolic and diastolic blood pressure, total cholesterol, LDL
cholesterol, insulin sensitivity; and measures of physical
activity require fewer participants to reach statistical
power (range n = 8–14, α = 0.05, power 0.8).
Randomisation
Participants will be randomised individually by a re-
searcher external to the project and will have no contact
with the participants prior to or during the trial. This re-
searcher will have no intellectual or personal investment
into the study design or outcomes. The women will be
randomised into either (ER) or (EXER) groups using
sealed opaque envelopes in blocks of six. The envelopes
will be stored in a locked cabinet within the independent
researcher’s office. Each envelope will contain a single
sheet of paper identifying the group allocation. The
sheet of paper will be folded at least twice to reduce
chance of transparency. One envelope will be chosen at
random from the stack of six envelopes containing three
of each group allocation (EX and EXER) reduced to a
single envelope; this is then combined with the next
group of six envelopes to reduce the chance of predict-
ability. The independent researcher is provided with a
participant identification number and completes ran-
domisation once the prospective participant provides the
study investigators (CM, TR, DV or JD) with a medical
clearance from their own general practitioner, preliminary
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measures to ensure safety and suitability for study partici-
pation. Participants, and researchers involved in delivering
participant interventions will not be blinded to group allo-
cation. Some of these researchers (CM, DV, TR) will also
be involved in study co-ordination and data collection.
Study interventions
Energy restriction
All participants in ER and EXER follow the same struc-
tured Optifast® clinical treatment protocol. In summary,
the participant will meet with an accredited practicing
dietitian who forms part of the research team every fort-
night for the first 12 weeks. This will be continued as
clinically relevant for the remaining 9 months. The
VLED consists of four phases (intensive, 450–680 kcal;
transition, 800–880 kcal; maintenance, 1000–1400 kcal;
and stabilisation, 1200 kcal; phases). The phases and the
extent of energy restriction of the protocol are not fixed,
and will be modified as clinically relevant depending on
the participant’s ability to manage with the diet, weight
gain or loss, or the participant’s change in health cir-
cumstances. It is expected that not all participants will
feel comfortable following the Optifast® protocol for the
entire 12 months despite encouragement and support
and, therefore, the dietitian will work with the partici-
pant to create a suitable energy-restricted diet as per
standard clinical practice. All participants begin with an
intensive phase for up to 12 weeks, moving into the
transition phase for weeks 13–18 which incorporates
one whole food meal, completing weeks 19–22 in the
maintenance phase to introduce two whole food meals
per day, and the remaining 6 months in the stabilisation
phase where most meals will consist of whole food. As
part of standard clinical care, the study dieticians will
collect 4-day diet records at baseline and at each follow-
up period and, when required, use the 24-hour dietary
recall for tracking participant adherence and adjust the
dietary plan.
Exercise training
EXER follow a standardised progressive exercise
programme led by accredited exercise physiologists or a
student exercise physiologist supervised by an accredited
exercise physiologist. The exercise intervention consists
of a supervised exercise programme that is complemen-
ted by a home-based exercise routine. The supervised
exercise training will commence the same week as the
VLED and consists of the following:
3 × 1 hour supervised exercise sessions per week
(weeks 1–6)
2 × 1 hour supervised exercise session per week
(weeks 7–12)1 × 1 hour supervised exercise session per week
(weeks 13–26)
2 × 1 hour supervised exercise sessions per month
(weeks 27–52)
The exercise training will consist of a progressive
moderate intensity aerobic conditioning and resistance
training programme using a variety of machines and free
weights. Each training session lasts 60 minutes and will
consist of 5 minutes’ warm up, 45–50 minutes of condi-
tioning, and 5 minutes of cool-down and stretching. The
conditioning component consists of approximately 20–
30 minutes of aerobic training (12–16 on Borg’s Ratings
of Perceived Exertion (RPE) scale, 60–80 % heart rate
reserve (HRR)) followed by 20–30 minutes of resistance
exercise (one to three sets of eight to ten repetitions).
The resistance exercise involves six to ten different,
predominantly multi-joint exercises for the upper and
lower extremities at an intensity of two repetitions below
volitional fatigue, with a 2-second concentric and eccen-
tric contraction speed. Exercise prescription followed
clinical judgement and the American College of Sports
Medicine’s (ACSM’s) guidelines [76] to ensure fitness
improvement and programme compliance. Once partici-
pants complete three sets of ten repetitions with correct
technique, for two consecutive training sessions, the
resistance will be increased. The cardiorespiratory fitness
training progress from 40–60 % HRR in the first 5 weeks
to 60–80 % HRR for the remainder of the programme.
The mode of aerobic exercise varies depending on par-
ticipant’s choice; however, weight-bearing exercise such
as walking will be encouraged as one of the principle
exercise modes.
The exercise physiologists will follow a structured
resistance training programme with eight core exercises
that will include: leg press, squats, bench press, seated
row, lateral pull down, shoulder press, biceps curl and
triceps kickbacks.
The exercise physiologists will keep a record of attend-
ance, exercises undertaken and progress achieved by
participants. Any adverse events or adverse signs and
symptoms will be documented including feelings of gen-
eral fatigue, soft tissue soreness, light-headedness, colds
and flu and injury or illness. The reason for non-
attendance will also be included on the exercise
programme card. ‘Make up’ sessions will be made avail-
able where possible during the same training week or
the following week.
The participants will be assisted in the development of
a home-based exercise programme that will gradually
replace the supervised exercise sessions. This is a trans-
fer to a self-management model. The programme will
consist predominantly of cardiorespiratory exercise de-
vised around each individual’s access to facilities and
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increase incidental physical activity. Participants will
progressively increase the weekly hours and frequency of
home-based exercise during the period of the study so
that all participants aim to be exercising most if not all
days of the week. The participants will set a goal of exer-
cising at a moderate intensity for 200 minutes per week
in week 1, progressing to 300 minutes by week 6 and
sustaining this level of exercise participation for the
remainder of the 12-month intervention to assist with
developing a regular exercise habit conducive for weight
maintenance [77–79]. The purpose of the exercise physi-
ologist is to provide advice, guidance and support for the
prescription of exercise, and at no time will provide diet-
ary advice to the participants. Exercise physiologists will
advise participants to discuss dietary questions with the
study dietitians.
Participants randomised to the energy restriction only
group will be encouraged to exercise at study com-
mencement and during the dietary consultations along
with general lifestyle advice, but will not be provided
with any other specific guidance or follow-up support.
These participants will not be discouraged from chan-
ging their exercise habits.
Measures
Outcome measures will be obtained from participants at
baseline, 3, 6, and 12 months. The series of tests at each
location is shown in Fig. 1. Trained research staff will
adhere to the standardised procedures for all data collec-
tion ensuring consistency in (1) order of tests, (2) use
the same equipment for each test, and (3) management
and storage of data collected.
Primary outcome measures
Peak aerobic power
Peak aerobic power will be assessed using a symptom-
limited graded motorised treadmill (h/p/cosmos Quasar
DE83365, Nussdorf-Traunstein, Germany) test suitable
for those with low exercise tolerance. Participants warm
up at a comfortable walking pace at 0 % gradient and
speed is then adjusted gradually until RPE (6–20 Borg
point scale) of 8/20 is achieved. Participants will be coa-
ched and counselled on the RPE scale during the rest
period and as they progressively reach the test speed.
The speed will then remain constant for the duration of
the exercise test. During the test period the gradient is
increased by 2 % per minute until the participant sub-
jectively reports a 17 (very hard) on the Borg rating of
perceived exertion scale (RPEpeak = 17). The test will be
terminated earlier if adverse signs and symptoms arise.
The test will be terminated at an RPE of 17/20 to avoid
adverse signs and symptoms rather than reaching max-
imum volitional fatigue, which may increase the risk ofadverse events, or increased risk of withdrawal from the
study in this high-risk population. Using RPE for test
termination is a valid method of measuring peak aerobic
power [80–82]. Expired respiratory gases will be col-
lected through a breath-by-breath pneumotach system
(Innocor Innovision version 6.15, Glamsbjerg, Denmark).
The Innocor unit will be calibrated before each test
according to the manufacturer’s guidelines. The breath-
by-breath data will be integrated for each 15-second
interval and the mean values for VO2, VCO2 and ventila-
tion (VE) used for that interval. Heart rate (HR) will be
measured at rest and during the graded exercise test
using a 12-lead electrocardiogram (ECG) (Mortara, X-
Scribe II, Milwaukee, WI, USA). Heart rhythm and other
ECG characteristics will be continuously monitored
from this 12-lead system. Pulse oximetry (NONIN Med-
ical 2120, Plymouth, MN, USA) will be recorded at the
end of each minute during the test and recovery. Partici-
pants will be asked not to consume caffeine, alcohol or
tobacco for a minimum of 2 hours prior to the exercise
test. Resting pre-exercise and post-exercise blood pres-
sure will be measured using a manual sphygmomanom-
eter and stethoscope.
Muscular strength
Maximal muscular strength will be determined using a
three repetition maximum (3RM) [76] for bench press,
supine leg press, and seated row using standard resist-
ance training equipment. The participants will be
instructed and allowed to practice correct lifting and
breathing techniques for each exercise prior to the test
and will complete ten repetitions of the exercise at a low
to moderate load. This also serves as a specific warm up
to the exercise test. Participants will be asked to self-
select an estimated starting weight which will then be
increased gradually until only three repetitions are
possible. The progressive increase in load ranges from
1–10 kg for bench press, 2–10 kg for leg press and
1–9 kg for seated row. The rest period between
attempts is set to 90–120 seconds or until fully
recovered. The bench press will be performed using a
Smith machine (BodySolid, Powerline PSM144X,
Forest Park, IL, USA). The seated row will be com-
pleted using a dual pulley (Nautilus tower pulley
system, F3ATFS, Independence, VA, USA) with a V-
pulldown/row bar. The pulley height will be set in
line with the participant’s xiphoid process and feet
placed on a step to ensure a full arm length distance
from the pulley. The back and shoulders will rest on
the back of the upright bench to avoid the use of
momentum. The leg press (Synergy Omni leg press
S-31-OPD, QLD, Australia) will be performed in
supine with the seat lowered until the knee reaches
90°. For all strength tests, the machine settings in
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subsequent tests. Total muscle strength will be calcu-
lated as the sum of the three strength measures. Rela-
tive strength will be calculated by dividing total
strength by body mass in kilograms.
Body composition
Body composition and total body bone mineral density
will be assessed using a dual energy X-ray absorpti-
ometry (DXA) scanner (GE Lunar Prodigy Pro, Madison,
WI, USA) with software version 12.1 to assess total and
regional body fat mass, lean mass, and total body bone
mineral content and density. Prior to each assessment
standard manufacturer procedures for quality assurance
and quality control will be performed. All participants
will be wrapped using a light sheet to ensure the entire
body remains within the scan area. Due to the limited
scanning width of the DXA, modifications to the scan
will be completed and replicated during subsequent
scans. Participants will be aligned with the right hand
side of their body against the right edge of the scan field.
In some instances due to the width of obese participants,
the left upper extremity may fall outside of the scan
range. For these participants, the left upper extremity
will be replaced by the right upper extremity. For in-
stances where portions of the trunk lie outside of the
scan area, half body scans will be completed of the right
side and multiplied by two. The maximum static load
limit of the DXA at the Deakin University laboratory is
159 kg. Participants above this weight will be scanned at
the Alfred Hospital using a DXA scanner (GE Lunar
iDXA, Madison, WI, USA) with an upper weight limit of
200 kg. For all participants, follow-up testing will be
replicated to be consistent with that of the baseline test,
including body position, calculation, and equipment.
Secondary outcome measures
Body mass index
Weight will be measured using calibrated scales
(SECA 708, Hamburg, Germany), weighing to the
nearest 0.01 kg. Height will be determined using a
standard calibrated stadiometer (Holtain Limited,
Crymych, Pembrokeshire, UK) measured to the near-
est 0.01 metres with the participant standing in the
anatomical position. BMI will be calculated using the
following formula: weight (kg)/height (m2). Three
measurements will be taken and the mean of the two
closest measurements used.
Waist circumference
Waist circumference will be measured using a steel tape
measure with the participant in the standing position.
The tape will be placed horizontally around the partici-
pant’s waist immediately above the iliac crest accordingto the NHANES III procedure [83]. Three measure-
ments will be taken and the mean of the two closest
measurements will be used.Hip circumference
Hip circumference will be measured using a steel tape
measure with the participant in the standing position.
The tape will be placed horizontally around the
widest part of the hips [84]. Three measurements will
be taken, and the mean of the two closest measure-
ments used.Sit to Stand test in 30 seconds
The Sit to Stand test in 30 seconds (STS-30) as de-
scribed previously [85] will be performed as a functional
weight-bearing performance test for the lower body and
a test for lower limb muscular endurance. The test com-
mences following a demonstration of technique and
cueing from the researcher and is practised by the
participant for up to ten repetitions with feedback on
technique. The participant then rests for up to 3 mi-
nutes or until fully recovered before commencing the
30-second test. The test commences in the seated
position and the participants are instructed to hold
their arms across their chest for the test duration.
The participant will be required to sit back on the
chair but not collapse back into the chair prior to the
next repetition. If the participant is more than half
way up at the end of 30 seconds then the repetition
will be rounded up. The chair will be set at the
height of the popliteal crease and recorded to repli-
cate in later tests.Objective assessment of physical activity and sedentary
behaviour
Participants will be fitted with an Acti-heart® heart rate
and activity monitor that will be worn for 7 days as
described previously [86, 87]. The monitor is attached
by two standard electrodes on the chest, placed immedi-
ately lateral to the sternum at the second intercostal
space with the second electrode attached on the same
horizontal level as far lateral as possible. The area is
cleaned with a 73 % ethanol swab prior to electrode
placement. The device will be worn for seven consecu-
tive days without being removed (unless electrodes
require replacing) and data will be analysed to determine
the duration of sedentary behaviour (<1.5 METS), light
intensity (1.5–2.9 METS), and moderately intense activ-
ity (≥3 METS) [88] in bouts of at least 1 minute and at
least 10 minutes. Participants will be blinded to the
device’s ability to record activity data.
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Participants will complete the Baecke physical activity
questionnaire as a measure of habitual physical activ-
ity over the previous 12 months [89]. Separate work,
sport and leisure index scores will be calculated, plus
a total score.
Seven-day exercise recall
Participants will be interviewed during consultations
prior to the commencement of the physical tests. The
participant will be guided through a recall of the previ-
ous 7 days for engagement in exercise bouts of at least
10 minutes in duration. Intensity will be reported by the
participant through description of effort, breathing or
the use of the Borg scale for ratings of perceived exer-
tion [90]. The weekly time spent exercising at moderate
to vigorous intensity for bouts of at least 10 minutes will
be used for analysis. This lower limit was set due to a
lack of health benefits achieved at lower duration and
intensities [91].
Blood sampling and analysis
Fasting blood collection and analysis
Venous blood samples will be collected prior to the oral
glucose tolerance test (OGTT) by a trained phlebotomist.
Forty millilitres of blood will be extracted into vacutainer
tubes, and two tubes will be sent to a commercial path-
ology laboratory for analysis of fasting glucose, insulin,
blood lipids, haemoglobin A1c, and C-reactive protein.
The remaining blood will be centrifuged and stored in a
freezer at −80 °C. Markers of systemic inflammation and
bone metabolism will be analysed as described previously
[92, 93]. Each participant is advised to maintain their nor-
mal diet and exercise patterns for the 3 days prior to the
testing. After a 12- hour overnight fast, participants will at-
tend the Baker IDI Heart and Diabetes Institute. Baker IDI
Heart and Diabetes Institute research colleagues will per-
form muscle sympathetic nerve activity recording, endo-
thelial function assessment and the OGTT. An
intravenous catheter will be placed in an antecubital vein
for blood sampling. Volunteers will ingest 75 g of glucose
over 2 minutes (Glucotol™, Orion Laboratories, Welshport,
WA, Australia). Blood samples will be drawn at −15, 0, 30,
60, 90 and 120 minutes for determination of plasma
glucose and insulin concentrations. The remaining
blood will be centrifuged and plasma will be stored in
a freezer at −80 °C at the Baker IDI Heart and Dia-
betes Institute. Markers of bone metabolism and
systemic inflammation will be analysed as described
previously [92] from the stored samples.
Muscle sympathetic nerve activity (MSNA) recording
Recordings of multi-unit post-ganglionic MSNA will
be made while the subject rests in a comfortablesupine position. A tungsten microelectrode (FHC,
Bowdoinham, ME, USA) will be inserted directly into
the right peroneal nerve at the fibular head by an ex-
perienced investigator (EL). During MSNA recording,
blood pressure (BP) will measured continuously using
the Finometer system (Finapress Medical System BV,
Amsterdam, The Netherlands) and heart rate (HR)
will be extracted from a three-lead ECG. All of these
parameters will be digitised with a sampling frequency of
1000 Hz (PowerLab recording system, model ML 785/8SP,
ADInstruments, Bella Vista, NSW, Australia). Resting
measurements will be recorded over a 15-minute period
and averaged. Sympathetic bursts will be counted manu-
ally and expressed as burst frequency (bursts/minute) and
burst incidence (bursts/100 heart beats).
Twenty-four-hour ambulatory blood pressure monitoring
Participants will be fitted with ambulatory blood pres-
sure monitoring equipment (Oscillometric monitor,
model number 90207, SpaceLabs Medical Inc., WA,
USA) before leaving the Baker IDI Heart and Diabetes
Institute on the first day at each assessment timepoint.
The device will be worn around the waist with a belt
while the cuff will be fitted to the upper left arm to
measure brachial blood pressure every 15 minutes be-
tween 6 am and 10 pm, and every 30 minutes between
10 pm and 6 am. Participants will be advised to record
their activity and any symptoms at each reading. The
monitor is removed after 24–26 hours of continuous
wear and then returned via a self-addressed express post
satchel or in person to the Baker IDI Heart and Diabetes
Institute. Blood pressure values will be averaged over the
total recording time for a 24-hour average, and separ-
ately across waking and sleeping hours [94]. Resting
blood pressure will be also recorded in the clinic after
sitting quietly for 5 minutes. Blood pressure will be
taken by an experienced researcher using a standard
aneroid sphygmomanometer, listening for the first and
last Korotkoff sounds through the brachial artery with a
stethoscope.
Spontaneous cardiac baroreflex function
Baroreflex sensitivity will be assessed using the sequence
method from analysis of the continuous (beat-to-beat)
blood pressure and heart rate fluctuations. The proced-
ure identifies the ‘spontaneous’ sequences of three or
more consecutive beats in which systolic blood pressure
progressively rise (by at least 1 mmHg) and cardiac
interval lengthens, or systolic blood pressure progres-
sively falls (by at least 1 mmHg) and cardiac interval
progressively shortens, with a lag of one beat. For each
sequence, the linear correlation coefficient between car-
diac interval and systolic blood pressure will be com-
puted and the sequence validated when r >0.80. The
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sure will be calculated for each validated sequence and
an average slope will be calculated for each recording.
These measures will be extend by including assess-
ment of baroreceptor modulation of MSNA (or vaso-
motor tone) by relating each spontaneous sympathetic
burst to the diastolic blood pressure and cardiac
interval of the heart beat during which the burst is
generated [95].
Endothelial function
The Endo-PAT 2000 will be used to non-invasively
assess endothelial function and arterial stiffness. The
device captures a beat-to-beat plethysmographic record-
ing of the finger arterial pulse wave amplitude with
pneumatic probes, detecting the peripheral arterial tone.
Peripheral arterial tonometry is assessed in response to
reactive hyperemia by placing the finger probe on the
index finger in each hand (occluded study hand, and
non-occluded, control hand). Measurements will be ob-
tained for 5 minutes at baseline followed by 5 minutes
of occlusion of one arm, with cuff inflated on the upper
arm to supra-systolic pressure and then released to
induce reactive (flow-mediated) hyperaemia, measured
for 5–10 minutes. The magnitude of flow-mediated
hyperaemia is calculated as the ratio between post-
obstructive and baseline pulse wave amplitude, corrected
to systemic changes measure in the contralateral, non-
obstructed arm. Arterial stiffness is assessed by auto-
matic calculating the Augmentation Index from the
pulse arterial tonometry waveform.
Quality of life questionnaires
The Medical Outcomes Trust (MOT) SF-36 (short form
36) health-related quality of life questionnaire contains 36
questions regarding the multi-dimensions of health.
Question categories include: limitations of activities, gen-
eral health, physical health problems, emotional health
problems, social activities, pain, and energy and emotions
[96, 97]. The questionnaires will be printed and provided
to participants to complete at each timepoint.
Multi-dimensional Body-Self Relations Questionnaire
The Multi-dimensional Body-Self Relations Question-
naire is a validated questionnaire [98] and the Appear-
ance Orientation (AO) and Appearance Evaluation (AE)
subscales have previously been used in this patient
population [99]. AO quantifies the importance placed on
appearance and grooming, and is scored on five-point
responses (definitely disagree to definitely agree) to 12
questions. The AE score is comprised of seven items
(again with five-point responses) and describes the
participant’s perception of their own attractiveness.The Work Productivity and Activity Impairment
Questionnaire (WPAI) is a short self-report instrument
that requires the participant to recall their work prac-
tices over the past 7 days. It has been used previously to
assess work productivity loss and the degree of impair-
ment to activity due to obesity and obesity-related co-
morbidities [100].
Epworth Sleepiness Scale
The Epworth Sleepiness Scale assesses daytime sleepi-
ness during various situations on a four- point scale
from 0 (would never doze) to 3 (high chance of doz-
ing) [101].
Musculoskeletal Pain Questionnaire
Participants will complete an 11-point (0–10) Likert
visual analogue scale (VAS) to report pain in nine
regions around the body as described elsewhere [102].
Self-efficacy questionnaires
The Exercise Self-efficacy Scale (ESE) measures per-
ceived competence to overcome barriers to completing
exercise. The five items on the scale require the partici-
pant to rate the statement from 1 (not at all confident)
through to 7 (very confident). The second self-efficacy
scale, the Weight Efficacy Lifestyle Scale (WEL), mea-
sures self-efficacy for appropriate eating. It has five sub-
scales (negative emotions, availability, social pressure,
physical discomfort, positive activities) with four items
each. Each item presents a statement that is then ranked
on a 10-point scale, 0 (not confident) to 9 (very
confident) [103, 104].
Beck Depression Inventory-II
The Beck Depression Inventory-II (BDI) [105] is a revi-
sion of the original 21-item questionnaire with scores
ranging from 0 to 3 on a 4-point Likert-type scale for
each question (responses ranging from ‘not at all’ to an
extreme form of each symptom) used to assess severity
of depressive symptoms over the past 2 weeks including
the current day, in populations aged 13 years and over.
This tool is not used for diagnostic purposes, rather it is
used to identify and score the severity of symptoms of
depression.
Spielberger State and Trait Anxiety Inventory
The Spielberger State and Trait Anxiety Inventory
(STAI) is used to measure the presence and severity of
current symptoms of anxiety along with general ten-
dency to be anxious via self-report [106]. This tool con-
sists of two questionnaires of 20 items each, the first
questionnaire is used to measure state anxiety (feelings
of anxiety at the time of administration) while the
second, measures trait anxiety (general feelings of
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response scale from ‘not at all’ to ‘very much so’
(scored from 1 to 4) in the state anxiety questionnaire
and ‘almost never’ to ‘almost always’ (scored from 1
to 4) for trait anxiety [106]. Scores range from 20 to 80 for
each questionnaire with higher scores indicate greater
anxiety. A cut-point of 39 to 40 being set for clinically
significant symptoms of state anxiety [108, 109].
Statistical analysis
All variables will be plotted and visually inspected for
skewness and kurtosis. Formal analysis of normality will
be confirmed with the Kolmogorov-Smirnov test of nor-
mality (SPSS statistics for windows, version 21.0: IBM
Corp., Armonk, NY, USA) as it is appropriate when used
with small- to medium-sized samples [110]. The inde-
pendent t test for continuous variables will be used to
examine the groups (ER versus EXER) characteristics at
baseline using Genstat statistical software (for Windows
16th edition. VSN International, Hemel Hempstead,
UK). Genstat will be used to produce a histogram of
residuals, fitted-value and normal plot of residuals and
assessed for normality, independence, equal variance and
linearity for each dependent variable. If the data is
shown to not be normally distributed or displays hetero-
scedasticity the data will be log transformed to restore
normality [111]. Factorial repeated measures analysis of
variance (ANOVA) (mixed between-within subjects or
split-plot) with intention-to-treat protocol for all vari-
ables to assess the interaction effect (group × time) will
be performed. Missing values for variables will be
replaced using an expectation maximisation algorithm
with a multiple imputations method [112] using Genstat
statistical software. Analysis for the least significant
difference of the means will be performed for both time
and group with a p value set at 0.05.
Discussion
Previous research demonstrates various health benefits
of including exercise training as part of a healthy lifestyle
at all BMI ranges. Although clinical practice guidelines
recommend exercise training as part of the first-line
treatment for overweight and obesity, there are few stud-
ies that demonstrate the effectiveness of exercise in class
II and class III obesity. The study aims to determine
whether the addition of exercise training to a VLED pro-
vides more favourable improvements in body compos-
ition, physical function, quality of life, and markers of
cardiometabolic risk for women with clinically severe
obesity, compared to VLED alone. The results of this
study should allow for a greater understanding of the
benefits and limitations of exercise training for high risk
class II and class III obese women during periods of
energy-restricted weight loss. It is expected that thisresearch will guide clinical practice in the primary care
setting, so that clinicians can provide more informed
evidence-based practice for the management of clinically
severe obesity.
Trial status
The EMPOWER trial is active with participant recruit-
ment and intervention delivery currently ongoing.
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